CD96 and neoplasm: Similarly, anti-CD96 therapy reduces 4T1 or B16 tumours in the lung and this effect is enhanced by the addition of anti-CTLA-4, anti-PD-1 or doxorubicin chemotherapy.52 Likewise, Cd96–/– mice develop fewer experimental lung metastases than wild-type mice after tail vein injection of B16 cells, and this result is dependent on NK cells and interferon (IFN)γ.53 As both TIGIT and CD96 bind CD155, targeting both TIGIT and CD96 might be essential to achieve maximum anti-metastatic benefit.52